Downloads: 0
Research Paper | Pathology | Volume 15 Issue 6, June 2026 | Pages: 162 - 167 | India
Expression of Vegf and Endoglin in the Spectrum from Endometrial Hyperplasia to Endometrial Carcinoma
Abstract: Endometrial carcinoma develops through a sequence of pathological changes that often begin with endometrial hyperplasia and progress toward malignancy. Angiogenesis is a key biological process in this transformation, with vascular endothelial growth factor (VEGF) and endoglin (CD105) playing important roles in new blood vessel formation. This study evaluated VEGF expression and CD105-positive microvessel density in 100 cases of endometrial hyperplasia without atypia, endometrial hyperplasia with atypia/endometrial intraepithelial neoplasia, and endometrial carcinoma. Immunohistochemical analysis demonstrated a consistent rise in VEGF H-scores and CD105 microvessel density from benign lesions to premalignant conditions and finally to carcinoma. Statistical analysis showed significant differences among all histopathological groups, while receiver operating characteristic analysis confirmed strong diagnostic accuracy for both markers in distinguishing benign lesions from atypical and malignant lesions. Non-endometrioid carcinomas also exhibited higher angiogenic activity than endometrioid carcinomas. The findings highlight the close association between angiogenesis and endometrial lesion progression and support the use of VEGF and CD105 as valuable quantitative.
Keywords: Endometrial Carcinoma, Endometrial Hyperplasia, VEGF Expression, CD105, Angiogenesis
How to Cite?: Vanaja D, Jeshtadi Anunayi, Soumya Vellanki, Naval Kishore, "Expression of Vegf and Endoglin in the Spectrum from Endometrial Hyperplasia to Endometrial Carcinoma", Volume 15 Issue 6, June 2026, International Journal of Science and Research (IJSR), Pages: 162-167, https://www.ijsr.net/getabstract.php?paperid=SR26603190050, DOI: https://dx.dx.doi.org/10.21275/SR26603190050